Company intelligence / Profile preview

Hangzhou Grand Biologic Pharmaceutical Inc.

Hangzhou, Zhejiang Province, China

Ownership: Private
Development stage: Phase 3

Overview

The company has approved products including a Combined Bifidobacterium, Lactobacillus, Enterococcus and Bacillus product approved in China on March 2, 2006, for constipation and other indications. They also have products in various clinical stages including IND approval, Phase 1, and Phase 2 stages as of April 2025[2].

Therapeutic areas: GastroenterologyImmunologyMetabolic Disorders
Modalities: ProbioticsLive biotherapeutic products (LBPs)Enzyme
Industry: Biotech

Drug pipeline

10 assets

bifidobacterium quadruple live tablets

9 more assets in the full pipeline.

Request access →

Partnerships

TenNor Therapeutics (for rifasutenizol)CommBio Therapeutics

Beyond the preview

Go deeper on Hangzhou Grand Biologic Pharmaceutical Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hangzhou Grand Biologic Pharmaceutical Inc..

Explore the full profile